AKBA

Business Context and Reporting Period

Akebia Therapeutics, Inc. (AKBA) is a biopharmaceutical company focused on developing and commercializing therapeutics for kidney disease. This Form 10-K covers the fiscal year ended December 31, 2024. The company's portfolio centers on two commercial products: Auryxia (ferric citrate), used for hyperphosphatemia and iron deficiency anemia, and Vafseo (vadadustat), an oral HIF-PH inhibitor approved by the FDA in March 2024 for anemia due to chronic kidney disease (CKD) in dialysis patients. Vafseo shipments in the U.S. commenced in January 2025. Auryxia is scheduled to lose exclusivity (LoE) in the U.S. on March 20, 2025.

Key Financial Metrics

Note: The filing text does not provide a specific gross margin percentage, but Cost of Goods Sold was $63.2 million in 2024, including $36.0 million in amortization of intangible assets.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 18% to $160.2 million. Net product revenue fell 11% to $152.2 million, primarily due to reduced Auryxia sales volume, partially offset by price increases. License and collaboration revenue dropped 67% to $8.0 million, largely due to the absence of a one-time $10.0 million upfront payment from Medice recognized in 2023.
• Increased Net Loss: Net loss widened 34% to $69.4 million. This was driven by a significant increase in "Other expense, net" to $18.1 million (from $5.1 million), primarily due to $9.3 million in non-cash interest expense related to the reclassification of the Vifor settlement liability as debt.
• Expense Management: Research and Development (R&D) expenses decreased 40% to $37.7 million due to the completion of certain clinical trials and reduced consulting costs. Selling, General, and Administrative (SG&A) expenses increased 6% to $106.5 million, driven by marketing costs for the Vafseo U.S. launch.
• Debt Restructuring: The company repaid its Pharmakon Term Loans in January 2024 and entered into a new BlackRock Credit Agreement, drawing $45.0 million in total tranches during the period (with the final tranche drawn in February 2025).

Guidance, Outlook, and Risks

• Vafseo Commercialization: The company aims to drive Vafseo to become the standard of care for anemia in CKD dialysis patients. It has secured supply agreements with dialysis organizations covering nearly 100% of U.S. dialysis patients. A Phase 3 cardiovascular outcome study (VALOR) for non-dialysis patients is planned for initiation in the second half of 2025.
• Auryxia Loss of Exclusivity: Auryxia faces generic competition starting March 20, 2025. Management believes the shift of Auryxia reimbursement into the Medicare ESRD bundle may result in a slower revenue decline than typical LoE scenarios, though this depends on contract retention and generic pricing.
• Liquidity: Management believes existing cash resources ($51.9 million) and expected revenues are sufficient to fund operations for at least 24 months. However, the company anticipates continued losses and may require additional financing.
• Material Weakness in Internal Controls: The company identified a material weakness in internal control over financial reporting related to inventory accounting and product sales forecasts. This weakness was not fully remediated as of December 31, 2024, resulting in a qualified opinion from auditors on internal controls.
• Regulatory and Legal Risks: Risks include the potential for Vafseo label expansion delays, the impact of the Inflation Reduction Act on drug pricing, and ongoing opposition proceedings regarding patents in India and Europe.

Investor Verification Checklist

• Inventory Valuation: Verify the remediation plan for the material weakness in inventory controls and the accuracy of the $3.6 million excess firm purchase commitment liability.
• Auryxia LoE Impact: Monitor Q1 2025 revenue trends to assess the actual impact of generic entry and the ESRD bundle reimbursement shift on Auryxia sales.
• Vafseo Adoption Rates: Track early commercial uptake and protocol adoption rates among major dialysis organizations (DaVita, Fresenius, USRC) following the January 2025 launch.
• Debt Covenants: Confirm compliance with BlackRock Credit Agreement covenants, specifically the requirement to maintain either $15.0 million in cash or $150.0 million in trailing twelve-month revenue.
• Valuation of Settlement Liability: Review the assumptions used to calculate the $52.6 million liability related to the Vifor Termination Agreement, which carries a 41% effective interest rate.